John F. Ward

Cancer ablation with regional templates applied to prostatectomy specimens from men who were eligible for focal therapy

P. Troncoso, R. Babaian, L. Pisters, 2009, BJU international.

Relationship between illness uncertainty, anxiety, fear of progression and quality of life in men with favourable‐risk prostate cancer undergoing active surveillance

D. Kuban, Andrew K. Lee, C. Logothetis, 2016, BJU international.

Correlation of prostate‐specific antigen nadir and biochemical failure after high‐intensity focused ultrasound of localized prostate cancer based on the Stuttgart failure criteria – analysis from the @‐Registry

X. Rébillard, C. Robertson, G. Conti, 2011, BJU international.

Free‐to‐total prostate‐specific antigen ratios 18–24 months following external beam radiation for adenocarcinoma of the prostate

C. Kane, P. Johnstone, J. Ward, 1999, Journal of surgical oncology.

Primary Whole-gland Ablation for the Treatment of Clinically Localized Prostate Cancer: A Focal Therapy Society Best Practice Statement.

T. D. de Reijke, J. Chin, E. Crawford, 2023, European urology.

Immune and pathologic responses in patients with localized prostate cancer who received daratumumab (anti-CD38) or edicotinib (CSF-1R inhibitor)

C. Drake, P. Sharma, P. Troncoso, 2023, Journal for ImmunoTherapy of Cancer.

Focal cryotherapy for localized prostate cancer: a report from the national Cryo On‐Line Database (COLD) Registry

J. Ward, J. Jones, John F. Ward, 2012, BJU international.